Jacc's Audio Podcasts

In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

Listen to the editor's page of the March 25th JACC issue, in which Harlan M. Krumholz, MD, SM, FACC, highlights how cardiac electrophysiology is undergoing significant transformation driven by technological advancements and evolving treatment strategies. Key topics include long-term insights from the AMPLATZER Amulet trial, the role of intracardiac electrograms in ventricular tachycardia ablation, and shifting anticoagulation strategies in atrial fibrillation. The issue also emphasizes the growing role of device-based therapies, such as leadless pacemakers, and explores the intersection of electrophysiology with structural cardiology and precision medicine.

In this video on research published in JACC and presented at ACC.25, Yuan Lu, ScD, JACC: Executive Associate Editor, discusses her study on optimal blood pressure management for adults aged 80 and above. Her study found that systolic blood pressure below 130 mmHg is associated with lower cardiovascular risk, while levels above 145 mmHg increase heart-related mortality. The study supports intensive blood pressure management but emphasizes the need for personalized treatment and further research on long-term effects and potential risks.#jacc #jaccjournals #acc25

Join JACC: Executive Associate Editor Mitsuaki Sawano, MD, FACC, and author Mats Lassen, MD discuss Dr. Lassen’s study on the link between acute respiratory syncytial virus (RSV) infection and an increased incidence of cardiovascular events, particularly in older adults, using comprehensive nationwide data from Denmark. The findings, published in JACC and presented at ACC.25, highlight the need for heightened awareness among healthcare providers, potential adjustments in patient management during RSV season, and further research into whether RSV vaccines may help reduce cardiovascular complications. #jacc #jaccjournals #acc.25

In this video discussion with JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, and authors Eric Hall, MD and James A. de Lemos, MD, FACC, they review this study published in JACC & presented at ACC.25. Do patients who survive cardiogenic shock have neurocognitive consequences at intermediate-term follow-up? New cognitive impairment is common at discharge and 3 months after CS and is associated with worse quality of life and functional status. #jacc #jaccjournals #acc25

In this brief report from the BMC2 registry published in JACC and presented at ACC.25, Eric Cantey, MD, FACC, and Celina Yong discuss the study findings. In light of the DanGer Shock Trial, there is a need to define the current practice patterns in the care of AMI-CS. There is overall low annual case volumes of AMI-CS with significant heterogeneity in the intraprocedural utilization of MCS and RHC.

Hosts Mitsuaki Sawano, MD, and Shun Kohsaka, MD, FACC, discuss the end of Skype and before welcoming Dr. Nobuyuki Kagiyama, MD (Juntendo University), to explore findings from the SONIC-HF Registry on the prognostic value of diaphragm ultrasound in heart failure patients. The episode covers ultrasound methodology, research challenges, and clinical implications for heart failure management.

Listen to the editor's page of the March 18th JACC issue, Harlan M. Krumholz, MD, SM, and Kushal T Kadakia, MSc, examine the troubled history of the Select IVC filter, a device approved by the FDA in 2007, which was later linked to severe safety issues due to clinical trial misconduct and regulatory oversights. In this audio version of their page, they note that the case reveals systemic vulnerabilities in medical research, regulation, and publication practices, emphasizing the importance of transparency, rigorous oversight, and ethical conduct in medical device development. They propose key actions for regulators, industry, medical journals, and clinicians to improve patient safety, trust, and the integrity of medical research.

In this episode, Dr. Valentin Fuster dives into a groundbreaking scientific statement from the American Heart Association and American College of Cardiology, providing updated clinical considerations for competitive athletes with cardiovascular abnormalities. The statement, which integrates 40 years of research, focuses on preventing sudden cardiac death and improving shared decision-making strategies for athletes facing heart conditions, offering expert guidance across 11 key task forces.

In this podcast highlights the growing concern over transcatheter valve failure following transcatheter aortic valve replacement (TAVR), emphasizing the need for standardized imaging protocols and frequent follow-ups. Experts discuss best practices for monitoring and managing these patients, urging collaborative international efforts to validate new imaging techniques and improve patient outcomes.

In this episode, Dr. Valentin Fuster discusses a groundbreaking study on the link between cigarette smoking and subclinical cardiovascular harm, focusing on markers of inflammation, thrombosis, and atherosclerosis. The research, based on data from over 182,000 participants across 22 cohorts, reveals how smoking intensity and duration impact early cardiovascular damage and highlights the potential of these biomarkers in shaping future public health strategies and regulatory policies.

In this episode, Dr. Valentin Fuster highlights a groundbreaking study on acoramides, a novel treatment for transthyretin amyloid cardiomyopathy (ATTR), which shows significant reductions in mortality and cardiovascular hospitalizations compared to a placebo. Experts discuss the clinical implications, comparing acoramides to the previously approved tafamidis, noting exciting advancements in treatments for a once-untreatable disease.

In this episode, Dr. Valentin Fuster discusses a 14-year study on the clinical impact of genetic testing for inherited cardiovascular diseases, conducted by Dr. Steffany Grondin at the Montreal Heart Institute. The study found that genetic testing helped diagnose 24% of patients, refine clinical management, and improve variant interpretation, while also highlighting the need for more research and better access to genetic expertise in healthcare.

In this episode, Dr. Valentin Fuster discusses a study on sodium zirconium cyclosilicate (SZC) for managing hyperkalemia in heart failure patients on mineralocorticoid receptor antagonists (MRAs) like spironolactone. While SZC effectively reduced hyperkalemia and allowed higher spironolactone doses, concerns over worsening heart failure events highlight the complex balance between treatment benefits and risks.

In this episode, Dr. Valentin Fuster highlights key research from the March 18th, 2025 issue of the JACC. The studies cover groundbreaking findings in heart failure management, genetic testing in cardiovascular diseases, the effectiveness of a new drug for amyloidosis, and the cardiovascular harm caused by smoking, offering valuable insights for clinical practice and patient care.

In this week's JACC Baran (Episode 4), hosts Mitsuaki Sawano, MD, JACC Executive Associate Editor, and Shun Kohsaka, MD, FACC, JACC Regional Editor welcome Koshiro Sakai, MD, to discuss the 2025 revised ACS guidelines and Photon-Counting CT (PCD-CT). A retrospective cohort study of 7,500 cases suggested an association between PCD-CT and enhanced diagnostic accuracy, with potential implications for reducing unnecessary invasive catheterization procedures. The episode also highlights global research perspectives and the importance of clear scientific communication.

The field of transcatheter aortic valve replacement (TAVR) continues to evolve, with new research expanding its indications and refining its application. This JACC special issue brings together cutting-edge studies, meta-analyses, and expert perspectives on key topics shaping the future of TAVR. Highlights include pivotal trials assessing TAVR in low-risk patients, a growing focus on moderate aortic stenosis and heart failure, and novel insights into reintervention strategies. The issue also presents comprehensive analyses on asymptomatic severe aortic stenosis, valve durability, and patient selection for next-generation TAVR applications. As TAVR increasingly moves beyond its initial role in high-risk patients, the studies featured here provide essential data to guide clinical decision-making, optimize outcomes, and address the challenges of valve longevity, structural durability, and patient-centric approaches. We hope this collection informs and inspires continued innovation in structural heart disease man

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.